MXPA01008056A - Forma cristalina de eplerenona que exhibe velocidad de disolucion intensificada. - Google Patents

Forma cristalina de eplerenona que exhibe velocidad de disolucion intensificada.

Info

Publication number
MXPA01008056A
MXPA01008056A MXPA01008056A MXPA01008056A MXPA01008056A MX PA01008056 A MXPA01008056 A MX PA01008056A MX PA01008056 A MXPA01008056 A MX PA01008056A MX PA01008056 A MXPA01008056 A MX PA01008056A MX PA01008056 A MXPA01008056 A MX PA01008056A
Authority
MX
Mexico
Prior art keywords
crystalline form
dissolution rate
exhibiting enhanced
enhanced dissolution
form exhibiting
Prior art date
Application number
MXPA01008056A
Other languages
English (en)
Inventor
Barton Kathleen
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of MXPA01008056A publication Critical patent/MXPA01008056A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MXPA01008056A 1999-12-08 2000-12-04 Forma cristalina de eplerenona que exhibe velocidad de disolucion intensificada. MXPA01008056A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16960899P 1999-12-08 1999-12-08
US16980799P 1999-12-08 1999-12-08
US16969099P 1999-12-08 1999-12-08
US16963999P 1999-12-08 1999-12-08
US16955699P 1999-12-08 1999-12-08
US16968299P 1999-12-08 1999-12-08
PCT/US2000/032416 WO2001042272A2 (en) 1999-12-08 2000-12-04 Eplerenone crystalline form exhibiting enhanced dissolution rate

Publications (1)

Publication Number Publication Date
MXPA01008056A true MXPA01008056A (es) 2003-07-21

Family

ID=27558585

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01008056A MXPA01008056A (es) 1999-12-08 2000-12-04 Forma cristalina de eplerenona que exhibe velocidad de disolucion intensificada.

Country Status (18)

Country Link
EP (1) EP1177204A2 (es)
JP (1) JP2003516414A (es)
KR (1) KR100607923B1 (es)
CN (2) CN1557833A (es)
AU (1) AU784946B2 (es)
BR (1) BR0008057A (es)
CA (1) CA2362669A1 (es)
CO (1) CO5280211A1 (es)
EA (1) EA007934B1 (es)
HK (1) HK1050536A1 (es)
HU (1) HUP0203032A3 (es)
IL (3) IL144764A0 (es)
MX (1) MXPA01008056A (es)
MY (1) MY131878A (es)
NO (1) NO20013856L (es)
NZ (2) NZ530028A (es)
PE (1) PE20010917A1 (es)
WO (1) WO2001042272A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04009037A (es) * 2002-03-20 2005-01-25 Pharmacia Corp Formulacion de eplerenona de almacenamiento estable.
US7235655B2 (en) 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
CA2582496A1 (en) 2007-03-20 2008-09-20 Apotex Pharmachem Inc. Improved process for the preparation and purification of eplerenone
US8957052B2 (en) 2010-05-10 2015-02-17 Universite Paris Descartes Methods and compositions for the treatment of fluid accumulation in and/or under the retina
JP6180930B2 (ja) 2010-06-16 2017-08-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 創傷治癒過程における再上皮化を刺激するための方法及び組成物
ES2846835T3 (es) 2015-10-13 2021-07-29 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para el tratamiento de la neovascularización coroidea
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
CN108059648A (zh) * 2017-12-30 2018-05-22 合肥久诺医药科技有限公司 一种依普利酮溶剂合物及其制备方法
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea
WO2023204729A1 (ru) * 2022-04-19 2023-10-26 Общество с ограниченной ответственностью "Гелеспон" Фармацевтические композиции на основе новой субстанции 4-[2-(1н-имидазол-4-ил)-этилкарбамоил]-бутановой кислоты и способ получения субстанции

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI77669C (fi) * 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
DE69716116T2 (de) * 1996-12-11 2003-09-04 Searle & Co VERFAHREN ZUR HERSTELLUNG VON 3-KETO-7alpha-ALKOXYCARBONYL- delta4,5-STEROIDEN SOWIE ZWISCHENPRODUKTE
NZ514205A (en) * 1999-03-05 2004-07-30 G Combination therapy of angiotensin converting enzyme inhibitor and the epoxy-steroidal aldosterone antagonist eplerenone for treatment of cardiovascular disease

Also Published As

Publication number Publication date
CN1152886C (zh) 2004-06-09
HUP0203032A3 (en) 2003-04-28
WO2001042272A9 (en) 2002-12-12
WO2001042272A3 (en) 2001-11-29
EP1177204A2 (en) 2002-02-06
WO2001042272A2 (en) 2001-06-14
AU784946B2 (en) 2006-08-03
KR20010112261A (ko) 2001-12-20
IL176511A (en) 2007-08-19
CA2362669A1 (en) 2001-06-14
BR0008057A (pt) 2002-04-23
PE20010917A1 (es) 2001-09-10
EA007934B1 (ru) 2007-02-27
HUP0203032A2 (hu) 2002-12-28
KR100607923B1 (ko) 2006-08-04
NZ513961A (en) 2004-02-27
NO20013856D0 (no) 2001-08-08
NO20013856L (no) 2001-10-08
IL144764A0 (en) 2002-06-30
IL144764A (en) 2007-08-19
CN1557833A (zh) 2004-12-29
NZ530028A (en) 2005-08-26
CO5280211A1 (es) 2003-05-30
EA200100871A1 (ru) 2002-04-25
CN1377365A (zh) 2002-10-30
MY131878A (en) 2007-09-28
HK1050536A1 (en) 2003-06-27
JP2003516414A (ja) 2003-05-13
AU2049201A (en) 2001-06-18

Similar Documents

Publication Publication Date Title
ZA200200741B (en) Oral liquid compositions.
EP1118915A4 (en) WATCH
HK1041649A1 (en) Cilostazol preparation.
ZA200110413B (en) Crystalline 1-methylcarbapenem compounds.
GB2356092B (en) Delay line
HK1050536A1 (en) Eplerenone crystalline form exhibiting enhanced dissolution rate.
GB0016698D0 (en) Tie
HUP0201795A3 (en) Disinfectants
HK1046642A1 (en) Novel diphenylethylene compounds.
IL144455A0 (en) 16-hydroxyestratrienes as selective estrogens
HK1057220A1 (en) Eplerenone crystalline form
MXPA00007601A (es) Cronometro.
HK1055954A1 (en) Crystalline therapeutic agent.
AU5092001A (en) Crystalline pharmaceutical
ZA200107145B (en) Eplerenone crystalline form exhibiting enhanced dissolution rate.
MXPA01013317A (es) Maquina para cristalizacion.
EP1157700A4 (en) ANTI-HIV AGENT
HUP0003380A2 (en) Reversible plough
GB2353580B (en) Blockage buster
CA89270S (en) Tie
GB9910326D0 (en) Ploughs
GB9925372D0 (en) Tie
CA86886S (en) Spoon
GB9914843D0 (en) Perforation
ZA991824B (en) Towel.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal